Ibrutinib Plus Liso-Cel Drives Deep Remissions in R/R CLL/SLL
Adding the covalent Bruton’s tyrosine kinase inhibitor ibrutinib to lisocabtagene maraleucel (liso-cel) drives deep, durable remissions in patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, offering ... Read More